Your browser doesn't support javascript.
loading
Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy.
Woriax, Hannah E; Thomas, Samantha M; Plichta, Jennifer K; Rosenberger, Laura H; Botty van den Bruele, Astrid; Chiba, Akiko; Hwang, E Shelley; DiNome, Maggie L.
Afiliação
  • Woriax HE; Division of Surgical Oncology, Department of Surgery, Duke University School of Medicine, Durham, NC.
  • Thomas SM; Duke Cancer Institute, Durham, NC.
  • Plichta JK; Duke Cancer Institute, Durham, NC.
  • Rosenberger LH; Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC.
  • Botty van den Bruele A; Division of Surgical Oncology, Department of Surgery, Duke University School of Medicine, Durham, NC.
  • Chiba A; Duke Cancer Institute, Durham, NC.
  • Hwang ES; Division of Surgical Oncology, Department of Surgery, Duke University School of Medicine, Durham, NC.
  • DiNome ML; Duke Cancer Institute, Durham, NC.
J Clin Oncol ; 42(14): 1635-1645, 2024 May 10.
Article em En | MEDLINE | ID: mdl-38394476
ABSTRACT

PURPOSE:

Black women have higher rates of death from triple-negative breast cancer (TNBC) than White women. We hypothesized that pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and overall survival (OS) may vary by race/ethnicity in patients with TNBC.

METHODS:

We identified women 18 years and older with stage I-III TNBC who received NAC followed by surgery from the National Cancer Database (2010-2019). We excluded patients without race/ethnicity or pathology data. Primary outcomes were pCR rates and OS on the basis of race/ethnicity.

RESULTS:

Forty thousand eight hundred ninety women with TNBC met inclusion criteria (median age [IQR], 53 [44-61] years) 26,150 Non-Hispanic White (64%, NHW), 9,672 Non-Hispanic Black (23.7%, NHB), 3,267 Hispanic (8%), 1,368 Non-Hispanic Asian (3.3%, NHA), and 433 Non-Hispanic Other (1.1%, NHO) patients. Overall, 29.8% demonstrated pCR (NHW 30.5%, NHB 27%, Hispanic 32.6%, NHA 28.8%, NHO 29.8%). Unadjusted OS was significantly higher for those with pCR compared with those with residual disease (5-year OS, 0.917 [95% CI, 0.911 to 0.923] v 0.667 [95% CI, 0.661 to 0.673], log-rank P < .001), and this association persisted after adjustment for demographic and tumor factors. The effect of achieving pCR on OS did not differ by race/ethnicity (interaction P = .10). However, NHB patients were less likely (odds ratio [OR], 0.89 [95% CI, 0.83 to 0.95], P = .001) and Hispanic patients were more likely (OR, 1.19 [95% CI, 1.08 to 1.31], P = .001) to achieve pCR than NHW patients. After adjustment for patient and disease factors, including achievement of pCR, Hispanic (hazard ratio [HR], 0.76 [95% CI, 0.69 to 0.85], P < .001) and NHA (HR, 0.64 [95% CI, 0.55 to 0.75], P < .001) race/ethnicity remained associated with OS.

CONCLUSION:

Odds of achieving pCR and OS in patients with TNBC appear to be associated with race/ethnicity. Additional research is necessary to understand how race/ethnicity is associated with rates of pCR and OS, whether related to socioeconomic factors or biologic variables, or both.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Neoadjuvante / Neoplasias de Mama Triplo Negativas Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Neoadjuvante / Neoplasias de Mama Triplo Negativas Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos